GSTM1 and coronary artery disorder: A cohort study with an average follow-up of 9.81 years that included patients with CAD and ACS investigated whether markers of immune activation were associated with disease severity of CAD and ACS (neopterin, interleukin (IL)-12, IL-6, high-sensitivity C-reactive protein (hs-CRP), fibrinogen, serum amyloid A and iron metabolism, ferritin, transferrin saturation, Hb) [33].